TCGA-AQ-A04L-01B-21R-A10J-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.340
- OXIDATIVE_PHOSPHORYLATION+0.330
- HYPOXIA+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- ANDROGEN_RESPONSE+0.280
- GLYCOLYSIS+0.270
- MTORC1_SIGNALING+0.260
- ADIPOGENESIS+0.250
- TGF_BETA_SIGNALING+0.180
- ANGIOGENESIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- MITOTIC_SPINDLE-0.380
- INTERFERON_GAMMA_RESPONSE-0.350
- E2F_TARGETS-0.280
- ALLOGRAFT_REJECTION-0.270
- G2M_CHECKPOINT-0.250
- WNT_BETA_CATENIN_SIGNALING-0.210
- COMPLEMENT-0.170
- IL6_JAK_STAT3_SIGNALING-0.100
- UNFOLDED_PROTEIN_RESPONSE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518241 | — | F | 0.836 |
| 2 | SRR8518414 | — | C | 0.822 |
| 3 | TCGA-AO-A12G-01A-11R-A10J-07 | — | A | 0.794 |
| 4 | SRR8518245 | — | F | 0.781 |
| 5 | C3L-01632 | — | cohortA4 | 0.760 |
| 6 | SRR8518181 | — | F | 0.759 |
| 7 | SRR8518340 | — | F | 0.740 |
| 8 | SRR8518146 | — | F | 0.734 |
| 9 | TCGA-CV-6935-01A-11R-1915-07 | — | — | 0.725 |
| 10 | SRR8518315 | — | F | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |